Montrouge, France, November 24, 2020
DBV Applied sciences Pronounces Management Adjustments
DBV Applied sciences (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Inventory Market: DBVT), a clinical-stage biopharmaceutical firm, immediately introduced that Dr. Hugh Sampson has determined to step down from his position as Chief Scientific Officer (CSO) at DBV, efficient December 1, 2020, to return to his analysis program on the Jaffe Meals Allergy Institute at Mount Sinai. Whereas appearing as CSO, Dr. Sampson continued his dedication to the meals allergy neighborhood by directing his analysis lab, working a NIH-sponsored prevention trial, and seeing sufferers in scientific apply part-time.
Dr. Sampson will tackle a brand new position as Scientific Adviser to the Chief Government Officer and Chairman of DBV’s Scientific Advisory Board. On this capability, he’ll stay concerned in DBV’s ongoing growth of epicutaneous immunotherapy (EPIT™).
After three years serving on DBV’s Scientific Advisory Board, Dr. Sampson joined DBV in 2015 to formally lead the Firm’s world scientific efforts and discover potential new purposes of investigational Viaskin™ for the therapy of meals allergic reactions and autoimmune problems, and for the event of novel vaccines. Dr. Sampson is the Kurt Hirschhorn Professor of Pediatrics on the Icahn Faculty of Drugs at Mount Sinai and the Director Emeritus of the Jaffee Meals Allergy Institute. He’s a member of the Nationwide Academy of Drugs, previous chair of the Part on Allergy & Immunology of the American Academy of Pediatrics and the past-president of the American Academy of Allergy, Bronchial asthma and Immunology.
“Hugh is universally thought to be a frontrunner in medical analysis in meals allergy and immunology. We’re honored that he has contributed his exceptional experience to advancing the Viaskin™ platform and shaping the scientific method to our potential meals allergy therapies. At the moment’s announcement is a part of a considerate transition course of, and we’re grateful that he’ll proceed to be an integral a part of our workforce in his new position,” mentioned Daniel Tassé, DBV’s Chief Government Officer. “I’d prefer to thank Hugh for his dedication to our pursuit of bettering affected person outcomes and his ongoing, steadfast management.”
“I’ve all the time been impressed by the dedication and vitality of everybody at DBV, and it has been an honor for me to behave as DBV’s Chief Scientific Officer for the previous 5 years,” mentioned Dr. Sampson. “I’m happy with what DBV has achieved in higher understanding the biology of EPIT and its potential purposes. Now’s the best time for me to return to Mount Sinai and deal with my analysis packages in novel diagnostics and prevention of meals allergy. Now we have labored with function to advance the potential behind the scientific profile of EPIT, and I’m excited by the likelihood that it could be a viable therapy choice for thousands and thousands of sufferers. I stay up for persevering with to work with DBV to advance their efforts in my new capability as Scientific Advisor to Daniel.”
About DBV Applied sciences
DBV Applied sciences is creating Viaskin™, an investigational proprietary expertise platform with broad potential purposes in immunotherapy. Viaskin is predicated on epicutaneous immunotherapy, or EPIT™, DBV’s methodology of delivering biologically energetic compounds to the immune system via intact pores and skin. With this new class of non-invasive product candidates, the Firm is devoted to soundly remodeling the care of meals allergic sufferers. DBV’s meals allergic reactions packages embrace ongoing scientific trials of Viaskin Peanut. DBV Applied sciences has world headquarters in Montrouge, France and places of work in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Firm’s bizarre shares are traded on section B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Firm’s ADSs (every representing one-half of 1 bizarre share) are traded on the Nasdaq World Choose Market (Ticker: DBVT).
Ahead Trying Statements
This press launch could include forward-looking statements and estimates, together with statements relating to the potential advantages of Viaskin Peanut, the Firm’s continued growth of epicutaneous immunotherapy, and the Firm’s transition plans. These forward-looking statements and estimates should not guarantees or ensures and contain substantial dangers and uncertainties. At this stage, the Firm’s merchandise haven’t been licensed on the market in any nation. Among the many components that might trigger precise outcomes to vary materially from these described or projected herein embrace uncertainties related usually with analysis and growth, scientific trials and associated regulatory evaluations and approvals, together with the impression of the COVID-19 pandemic. Moreover, the timing of any motion by any regulatory company can’t be assured. An extra checklist and outline of those dangers, uncertainties and different dangers may be discovered within the Firm’s regulatory filings with the French Autorité des Marchés Financiers, the Firm’s Securities and Trade Fee filings and reviews, together with within the Firm’s Annual Report on Kind 20-F for the 12 months ended December 31, 2019, and future filings and reviews by the Firm. Present and potential traders are cautioned to not place undue reliance on these forward-looking statements and estimates, which converse solely as of the date hereof. Apart from as required by relevant regulation, DBV Applied sciences undertakes no obligation to replace or revise the knowledge contained on this Press Launch.
Investor Relations Contact
+ 1 (857) 529-2363
+1 (646) 842-2393